{"id":"toripalimab-injection-js001","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Fatigue"},{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Rash"},{"rate":"5-10%","effect":"Pyrexia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting the PD-1/PD-L1 interaction, toripalimab allows T-cells to recognize and attack cancer cells more effectively. This mechanism is thought to be responsible for its anti-tumor activity.","oneSentence":"Toripalimab is a PD-1 inhibitor that blocks the PD-1/PD-L1 interaction to enhance T-cell mediated anti-tumor immunity.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:54:24.020Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic non-small cell lung cancer, PD-L1 positive"},{"name":"Metastatic nasopharyngeal carcinoma"},{"name":"Locally advanced or metastatic esophageal squamous cell carcinoma"}]},"trialDetails":[{"nctId":"NCT07214987","phase":"PHASE2","title":"PDT For Induction Therapy For Head And Neck Cancer","status":"NOT_YET_RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2026-03-09","conditions":"Squamous Cell Carcinoma, Head and Neck Cancer Squamous Cell Carcinoma, Head and Neck Cancer","enrollment":26},{"nctId":"NCT04284488","phase":"PHASE1, PHASE2","title":"Dose-escalation Study of APG-1387 and Toripalimab in Solid Tumors","status":"TERMINATED","sponsor":"Ascentage Pharma Group Inc.","startDate":"2020-04-10","conditions":"Advanced Solid Tumor","enrollment":40},{"nctId":"NCT05664971","phase":"PHASE1, PHASE2","title":"JS004 Combined With Toripalimab and With Standard Chemotherapy Treat Patients With Advanced Lung Cancer","status":"COMPLETED","sponsor":"Shanghai Junshi Bioscience Co., Ltd.","startDate":"2023-02-09","conditions":"Advanced Lung Cancer","enrollment":119},{"nctId":"NCT06178159","phase":"PHASE2","title":"DV in Combination With Pertuzumab With or Without Toripalimab Neoadjuvant Therapy With HER2-positive Breast Cancer","status":"RECRUITING","sponsor":"RemeGen Co., Ltd.","startDate":"2023-11-28","conditions":"Breast Cancer","enrollment":40},{"nctId":"NCT05980481","phase":"PHASE2, PHASE3","title":"A Study of RC48-ADC Combination Therapies as First-line Treatment in Advanced Metastatic Gastric Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"RemeGen Co., Ltd.","startDate":"2023-08-04","conditions":"Gastric Cancer","enrollment":201},{"nctId":"NCT03581786","phase":"PHASE3","title":"The Efficacy and Safety Study of TORIPALIMAB INJECTION Combined With Chemotherapy for Nasophapyngeal Cancer","status":"COMPLETED","sponsor":"Shanghai Junshi Bioscience Co., Ltd.","startDate":"2018-10-18","conditions":"Recurrent or Metastatic NPC","enrollment":289},{"nctId":"NCT03829969","phase":"PHASE3","title":"Toripalimab or Placebo With Paclitaxel and Cisplatin in Esophageal Squamous Cell Carcinoma","status":"COMPLETED","sponsor":"Shanghai Junshi Bioscience Co., Ltd.","startDate":"2019-01-31","conditions":"Advanced or Metastatic Esophageal Squamous Cell Cancer Without Previous Systemic Chemotherapy","enrollment":514},{"nctId":"NCT04991506","phase":"PHASE1","title":"A Study of ES102 (OX40 Agonist) in Combination With JS001 in Patients With Advanced Solid Tumors","status":"COMPLETED","sponsor":"Elpiscience Biopharma, Ltd.","startDate":"2021-10-15","conditions":"Solid Tumor, Neoplasms, Malignant Tumor","enrollment":30},{"nctId":"NCT02836795","phase":"PHASE1","title":"Safety and Tolerability of Recombinant Humanized Anti-PD-1 Monoclonal Antibody Toripalimab for Patients With Advanced Solid Tumors","status":"COMPLETED","sponsor":"Shanghai Junshi Bioscience Co., Ltd.","startDate":"2016-04","conditions":"Melanoma, Urological Cancer","enrollment":35},{"nctId":"NCT06919848","phase":"PHASE2","title":"Oncolytic Virus H101 Combined With Lenvatinib Plus Toripalimab Compared With FOLFOX in Patients With Advanced Biliary Tract Cancer (OPTIONS-06)","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2025-05-01","conditions":"Biliary Tract Cancer (BTC)","enrollment":74},{"nctId":"NCT06903871","phase":"PHASE2","title":"Toripalimab Adjuvant Therapy in Subjects With Resected Esophageal Squamous Cell Carcinoma Who Achieved Pathological Complete Response (pCR)","status":"NOT_YET_RECRUITING","sponsor":"Hebei Medical University Fourth Hospital","startDate":"2025-04-01","conditions":"Esophageal Squamous Cell Carcinoma Stage II, Esophageal Squamous Cell Carcinoma Stage III","enrollment":190},{"nctId":"NCT06889649","phase":"PHASE2","title":"SABR Combined with Axitinib and Toripalimab in Recurrent or Metastatic RCC","status":"RECRUITING","sponsor":"Peking University First Hospital","startDate":"2019-01-01","conditions":"Radiation Therapy, Targeted Therapy, Immunotherapy","enrollment":30},{"nctId":"NCT06712888","phase":"PHASE3","title":"Toripalimab Vs. Placebo Wtih GP Induction Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-02-17","conditions":"Nasopharyngeal Carcinoma (NPC)","enrollment":466},{"nctId":"NCT06571422","phase":"PHASE1","title":"Phase I Study of WJ47156 Monotherarpy and in Combination With Other Therapy in Advanced Solid Tumors","status":"RECRUITING","sponsor":"Shanghai Junshi Bioscience Co., Ltd.","startDate":"2024-10-23","conditions":"Advanced Malignant Solid Tumors","enrollment":93},{"nctId":"NCT05000684","phase":"PHASE1, PHASE2","title":"Study of JS004 Combined With Toripalimab for Advanced Lung Cancer","status":"COMPLETED","sponsor":"Shanghai Junshi Bioscience Co., Ltd.","startDate":"2021-08-27","conditions":"Advanced Lung Cancer","enrollment":67},{"nctId":"NCT05021328","phase":"PHASE1","title":"Toripalimab Combined With Anlotinib and SBRT in Patients With Untreated Brain Metastases of Driven Gene-negative NSCLC","status":"COMPLETED","sponsor":"Hubei Cancer Hospital","startDate":"2021-10-01","conditions":"NSCLC","enrollment":13},{"nctId":"NCT05033392","phase":"PHASE2","title":"PD-1 Blockade With JS001 Plus Neoadjuvant Chemotherapy for Gastric/Gastroesophageal Junction Cancer","status":"RECRUITING","sponsor":"Wan He","startDate":"2021-09-14","conditions":"Stomach Neoplasms","enrollment":62},{"nctId":"NCT06038396","phase":"PHASE1, PHASE2","title":"A Study of RC118 Plus Toripalimab / RC148 in Patients with Locally Advanced Unresectable or Metastatic Solid Tumors","status":"RECRUITING","sponsor":"RemeGen Co., Ltd.","startDate":"2023-08-03","conditions":"Advanced Solid Tumor","enrollment":48},{"nctId":"NCT04012606","phase":"PHASE3","title":"Toripalimab in Combination With Platinum Plus Etoposidein Patients With Extensive-Stage Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Shanghai Junshi Bioscience Co., Ltd.","startDate":"2019-07-23","conditions":"Small Cell Lung Cancer","enrollment":442},{"nctId":"NCT05180734","phase":"PHASE3","title":"PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shanghai Junshi Bioscience Co., Ltd.","startDate":"2022-02-10","conditions":"Gastric or Esophagogastric Junction Adenocarcinoma","enrollment":878},{"nctId":"NCT06709274","phase":"NA","title":"Minimal Residual Disease Guiding Adjuvant Therapy in Stage I NSCLC","status":"NOT_YET_RECRUITING","sponsor":"Guangdong Association of Clinical Trials","startDate":"2024-11","conditions":"Non-Small Cell Lung Cancer","enrollment":342},{"nctId":"NCT06705127","phase":"PHASE2","title":"Radiotherapy Followed by Chemotherapy Combined With Toripalimab in Local Advanced HR-positive,HER2-negative BC.","status":"RECRUITING","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2024-07-01","conditions":"HR-positive,HER2-negative Breast Cancer","enrollment":30},{"nctId":"NCT06389006","phase":"PHASE2","title":"To Evaluate the Efficacy and Safety of Disitamab Vedotin Combined With Toripalimab Sequential Chemotherapy as Neoadjuvant Treatment in Patients With HR-positive, HER2-low Breast Cancer","status":"RECRUITING","sponsor":"RemeGen Co., Ltd.","startDate":"2024-04-29","conditions":"Breast Cancer","enrollment":79},{"nctId":"NCT06370754","phase":"PHASE1, PHASE2","title":"Newly Emerging Immunotherapy for Pancreatic Cancer Treatment","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2024-04-30","conditions":"Pancreatic Cancer","enrollment":117},{"nctId":"NCT06227117","phase":"PHASE2","title":"Neoadjuvant Study of DV in Combination Toripalimab or Sequence Chemotherapy in HR-negative, HER2 Low-expressing Breast Cancer","status":"RECRUITING","sponsor":"RemeGen Co., Ltd.","startDate":"2023-07-27","conditions":"Breast Cancer","enrollment":120},{"nctId":"NCT04605185","phase":"PHASE1","title":"Donafenib and Toripalimab Combined With TACE in Patients With Unresectable Hepatocellular Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Suzhou Zelgen Biopharmaceuticals Co.,Ltd","startDate":"2021-01-08","conditions":"Unresectable Hepatocellular Carcinoma","enrollment":18},{"nctId":"NCT04137900","phase":"PHASE1","title":"Safety, Tolerability and Pharmacokinetics of a Monoclonal Antibody Specific to B-and T-Lymphocyte Attenuator (BTLA) as Monotherapy and in Combination With an Anti-PD1 Monoclonal Antibody for Injection in Subjects With Advanced Malignancies","status":"RECRUITING","sponsor":"TopAlliance Biosciences","startDate":"2019-10-30","conditions":"Advanced Unresectable Solid Tumor, Metastatic Solid Tumor","enrollment":499},{"nctId":"NCT05015621","phase":"PHASE3","title":"A Phase 3 Study to Evaluate Surufatinib Plus Toripalimab in the Treatment of Advanced Neuroendocrine Carcinoma","status":"UNKNOWN","sponsor":"Hutchison Medipharma Limited","startDate":"2021-09-18","conditions":"Advanced Neuroendocrine Carcinoma","enrollment":194},{"nctId":"NCT03867370","phase":"PHASE1, PHASE2","title":"Toripalimab in Combination With Lenvatinib as Neoadjuvant Therapy in Resectable Hepatocellular Carcinoma","status":"TERMINATED","sponsor":"Shanghai Junshi Bioscience Co., Ltd.","startDate":"2019-04-26","conditions":"Hepatocellular Carcinoma","enrollment":40},{"nctId":"NCT05979740","phase":"PHASE2","title":"RC48 Combined With Toripalimab and Radiotherapy for Bladder Sparing Treatment in MIBC","status":"UNKNOWN","sponsor":"RenJi Hospital","startDate":"2023-08-01","conditions":"Muscle Invasive Bladder Cancer, HER2 Expression, Radiotherapy","enrollment":6},{"nctId":"NCT06009705","phase":"","title":"Toripalimab Combined With Radiotherapy and S-1 for Older Patients With Esophageal Cancer","status":"RECRUITING","sponsor":"Hebei Medical University Fourth Hospital","startDate":"2022-10-01","conditions":"Esophageal Carcinoma","enrollment":56},{"nctId":"NCT05996484","phase":"PHASE2","title":"Neoadjuvant Therapy of Anlotinib Combined With Toripalimab and Chemotherapy for Resectable Esophageal Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2023-09","conditions":"Esophageal Carcinoma, Neoadjuvant Therapy","enrollment":25},{"nctId":"NCT03859128","phase":"PHASE2, PHASE3","title":"Toripalimab or Placebo as Adjuvant Therapy in Hepatocellular Carcinoma After Radical Resection","status":"UNKNOWN","sponsor":"Shanghai Junshi Bioscience Co., Ltd.","startDate":"2019-03-05","conditions":"Hepatocellular Carcinoma","enrollment":402},{"nctId":"NCT05751486","phase":"PHASE1","title":"A Clinical Study to Evaluate the Safety and Tolerability of JS001sc in Advanced Nasopharyngeal Carcinoma","status":"UNKNOWN","sponsor":"Shanghai Junshi Bioscience Co., Ltd.","startDate":"2022-10-21","conditions":"Advanced Nasopharyngeal Carcinoma","enrollment":24},{"nctId":"NCT04169672","phase":"PHASE2","title":"Study of Surufatinib Single Agent or Surufatinib Combined With Toripalimab in Patients With Advanced Solid Tumors","status":"COMPLETED","sponsor":"Hutchison Medipharma Limited","startDate":"2019-12-26","conditions":"Advanced Solid Tumors","enrollment":248},{"nctId":"NCT03856411","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Toripalimab or Placebo Combined With Chemotherapy in Treatment-naive Advanced NSCLC","status":"COMPLETED","sponsor":"Shanghai Junshi Bioscience Co., Ltd.","startDate":"2019-03-18","conditions":"Treatment-naive Advanced Non-small Cell Lung Cancer","enrollment":465},{"nctId":"NCT03924050","phase":"PHASE3","title":"Toripalimab Plus Pemetrexed+Platinus in Advanced Non-small-cell Lungcancer Patients Previsouly Treated EGFR-TKI","status":"UNKNOWN","sponsor":"Shanghai Junshi Bioscience Co., Ltd.","startDate":"2019-05-06","conditions":"Non-small Cell Lung Cancer","enrollment":440},{"nctId":"NCT04856631","phase":"PHASE1, PHASE2","title":"A Study of Toripalimab Injection (JS001) + Cetuximab in Treatment of Advanced Head and Neck Squamous Cell Cancer","status":"UNKNOWN","sponsor":"Shanghai Junshi Bioscience Co., Ltd.","startDate":"2021-04-06","conditions":"Head and Neck Squamous Cell Cancer","enrollment":88},{"nctId":"NCT04503902","phase":"PHASE1, PHASE2","title":"Toripalimab Combined With Donafenib in the Treatment of Advanced Hepatocellular Carcinoma","status":"UNKNOWN","sponsor":"Suzhou Zelgen Biopharmaceuticals Co.,Ltd","startDate":"2020-10-15","conditions":"Advanced Hepatocellular Carcinoma","enrollment":46},{"nctId":"NCT05453383","phase":"PHASE2","title":"Clinical Recruitment of Patients With First-line Targeted Drug Resistance or Intolerance to Hepatocellular Cancer With PD-1 Inhibitor (Toripalimab,JS001) Detected on the NGS Platform Combined With Anlotinib","status":"UNKNOWN","sponsor":"Shen Feng","startDate":"2022-07-08","conditions":"Hepatocellular Cancer","enrollment":30},{"nctId":"NCT04180995","phase":"PHASE2","title":"Toripalimab in Combination With Axitinib in Patients With Localized Mucosal Melanoma","status":"UNKNOWN","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2019-08-06","conditions":"Mucosal Melanoma","enrollment":30},{"nctId":"NCT04605796","phase":"PHASE2","title":"A Single-arm, Open-label, Multi-center Phase II Clinical Study to Evaluate the Safety and Efficacy of Toripalimab Injection (JS001) Combined With Bevacizumab as the First-line Therapy for Advanced Hepatocellular Carcinoma (HCC)","status":"UNKNOWN","sponsor":"Shanghai Junshi Bioscience Co., Ltd.","startDate":"2020-04-10","conditions":"Advanced Hepatocellular Carcinoma (HCC)","enrollment":54},{"nctId":"NCT05055583","phase":"PHASE2","title":"Toripalimab in Combination With Platinum-based Chemotherapy for Mutation-negative Stage IV Oligometastatic NSCLC","status":"UNKNOWN","sponsor":"Tang-Du Hospital","startDate":"2021-08-31","conditions":"NSCLC Stage IV, Oligometastasis","enrollment":30},{"nctId":"NCT04725448","phase":"PHASE2","title":"Toripalimab Combined With Bevacizumab, Nab-paclitaxel and Carboplatin for Untreated Metastatic Pulmonary Sarcomatoid Carcinoma","status":"UNKNOWN","sponsor":"Sichuan Cancer Hospital and Research Institute","startDate":"2021-04-06","conditions":"Pulmonary Sarcomatoid Carcinoma, Non-small Cell Lung Cancer, Lung Diseases","enrollment":27},{"nctId":"NCT04084158","phase":"PHASE2","title":"A Study of Toripalimab Combined With Concurrent Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma.","status":"SUSPENDED","sponsor":"Zhejiang Cancer Hospital","startDate":"2019-09-07","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":100},{"nctId":"NCT04731909","phase":"NA","title":"Toripalimab Combined With Anlotinib, Etoposide and Platinum in the Treatment of Extensive-stage Small Cell Lung Cancer","status":"UNKNOWN","sponsor":"Third Military Medical University","startDate":"2018-10-01","conditions":"SCLC, Extensive Stage, Lung Cancer, Small Cell Lung Cancer","enrollment":80},{"nctId":"NCT04211012","phase":"PHASE2","title":"A Study on Toripalimab Plus Nab-Paclitaxel With or Without Cisplatin as First-line Treatment of Urothelial Carcinoma","status":"UNKNOWN","sponsor":"Jun Guo","startDate":"2020-11-30","conditions":"Urothelial Carcinoma","enrollment":30},{"nctId":"NCT04603040","phase":"PHASE2","title":"A Study to Evaluate the Efficacy and Safety of Toripalimab Injection in the Treatment of Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Who Have Failed at Least Two Prior Lines of Therapy and Are Positive Specific Markers","status":"UNKNOWN","sponsor":"Shanghai Junshi Bioscience Co., Ltd.","startDate":"2020-09-28","conditions":"Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Who Have Failed at Least Two Prior Lines of Therapy","enrollment":100},{"nctId":"NCT03316144","phase":"PHASE1","title":"Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of Toripalimab for Patients With Recurrent Malignant Lymphoma","status":"COMPLETED","sponsor":"Shanghai Junshi Bioscience Co., Ltd.","startDate":"2017-07-12","conditions":"Malignant Lymphoma","enrollment":13},{"nctId":"NCT03178123","phase":"PHASE2","title":"The Study of JS001 Compared to High-Dose Interferon In Patients With Mucosal Melanoma That Has Been Removed by Surgery","status":"UNKNOWN","sponsor":"Shanghai Junshi Bioscience Co., Ltd.","startDate":"2017-05-31","conditions":"Mucosal Melanoma","enrollment":220},{"nctId":"NCT03113266","phase":"PHASE2","title":"Safety and Efficacy of Toripalimab for Patients With Locally Advanced or Metastatic Bladder Urothelial Carcinoma","status":"UNKNOWN","sponsor":"Shanghai Junshi Bioscience Co., Ltd.","startDate":"2017-04-06","conditions":"Bladder Urothelial Carcinoma","enrollment":370},{"nctId":"NCT03086174","phase":"PHASE1","title":"Tolerability and Pharmacokinetics of Toripalimab in Combination With Axitinib in Patients With Kidney Cancer and Melanoma","status":"UNKNOWN","sponsor":"Shanghai Junshi Bioscience Co., Ltd.","startDate":"2017-03-31","conditions":"Kidney Cancer Stage Iv, Advanced Melanoma","enrollment":24},{"nctId":"NCT03013101","phase":"PHASE2","title":"Safety and Efficacy of Recombinant Humanized Anti-PD-1 mAb for Patients With Locally Advanced or Metastatic Melanoma","status":"UNKNOWN","sponsor":"Shanghai Junshi Bioscience Co., Ltd.","startDate":"2016-12-28","conditions":"Advanced Melanoma, Metastatic Melanoma","enrollment":128},{"nctId":"NCT04568304","phase":"PHASE3","title":"A Study Evaluating Toripalimab Injection Combined With Standard Chemotherapy as a First-line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma","status":"UNKNOWN","sponsor":"Shanghai Junshi Bioscience Co., Ltd.","startDate":"2020-11-30","conditions":"Locally Advanced or Metastatic Urothelial Carcinoma","enrollment":364},{"nctId":"NCT04524884","phase":"PHASE2","title":"Toripalimab Combined With Surufatinib for Locally Advanced Thyroid Cancer: a Phase II Study","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2020-10-01","conditions":"Thyroid Cancer","enrollment":10},{"nctId":"NCT03848611","phase":"PHASE2","title":"CM082 and JS001 in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC).","status":"UNKNOWN","sponsor":"AnewPharma","startDate":"2019-04-02","conditions":"Non-small Cell Lung Cancer","enrollment":20},{"nctId":"NCT04459663","phase":"PHASE2","title":"JS001 Combination Therapy in NSCLC Negative Driving Gene After First-line Chemotherapy.","status":"UNKNOWN","sponsor":"Li Zhang, MD","startDate":"2020-08-31","conditions":"Non-small Cell Lung Cancer","enrollment":50},{"nctId":"NCT04363255","phase":"PHASE2","title":"First-line Chemotherapy Followed by Toripalimab Combined With Anlotinib for Maintenance in ES-SCLC","status":"UNKNOWN","sponsor":"Taizhou Hospital","startDate":"2020-05-01","conditions":"Small Cell Lung Carcinoma","enrollment":20},{"nctId":"NCT03941795","phase":"PHASE2","title":"Phase II Study in the Treatment of Patients With Advanced Mucinous Melanoma","status":"UNKNOWN","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2019-11-11","conditions":"Advanced Mucosal Melanoma","enrollment":99},{"nctId":"NCT02836834","phase":"PHASE1","title":"Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of an Anti-PD-1 mAb for Patients With Advanced Solid Tumors","status":"UNKNOWN","sponsor":"Shanghai Junshi Bioscience Co., Ltd.","startDate":"2016-08","conditions":"Lymphoma, Lung Cancer","enrollment":33},{"nctId":"NCT04126460","phase":"PHASE2","title":"High-risk Recurrent or Second Primary HNSCC With PD-1 Antibody Adjuvant After Salvage Surgery(RePASS)","status":"UNKNOWN","sponsor":"Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University","startDate":"2019-07-10","conditions":"Head and Neck Cancer","enrollment":41}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Epirubicin","cyclophosphamide","nab-paclitaxel"],"phase":"phase_3","status":"active","brandName":"TORIPALIMAB INJECTION(JS001 )","genericName":"TORIPALIMAB INJECTION(JS001 )","companyName":"First Affiliated Hospital of Zhejiang University","companyId":"first-affiliated-hospital-of-zhejiang-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Toripalimab is a PD-1 inhibitor that blocks the PD-1/PD-L1 interaction to enhance T-cell mediated anti-tumor immunity. Used for Metastatic non-small cell lung cancer, PD-L1 positive, Metastatic nasopharyngeal carcinoma, Locally advanced or metastatic esophageal squamous cell carcinoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}